Biological properties of ristocetin-ps-aglycone.
Ristocetin-ps-aglycone obtained by acid hydrolysis of ristocetin A, has a substantially greater antimicrobial activity against Gram-positive bacteria than the parent compound. None of the substances are active against Gram-negative bacteria, yeast or fungi. The ps-aglycone is several times more toxic than ristocetin A when administered intravenously. Both substances are well-tolerated when given subcutaneously, intraperitoneally and perorally. Both ristocetin A and the ps-aglycone have a very low absorption after oral administration. Plasma levels following intravenous administration of ristocetin A and the ps-aglycone are comparable, with both showing a rapid decline during the first 60 minutes followed by a somewhat slower elimination. The aggregating properties of the ps-aglycone could not be determined due to its low solubility at neutral pH.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000097:blood / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D005658:Fungi / Q000187:drug effects; D006863:Hydrogen-Ion Concentration; D006868:Hydrolysis; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D010974:Platelet Aggregation / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D012310:Ristocetin / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D012310:Ristocetin; C036975:ristocetin-psi-aglycone